Astrazeneca (AZN) Projected to Post Earnings on Monday

Astrazeneca (NYSE:AZN) is projected to issue its Q2 2026 results before the market opens on Monday, July 27th. Analysts expect the company to announce earnings of $2.10 per share and revenue of $15.4445 billion for the quarter. Individuals can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Monday, July 27, 2026 at 6:45 AM ET.

Astrazeneca (NYSE:AZN) last issued its earnings results on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.52 by $0.06. The firm had revenue of $15.29 billion during the quarter, compared to the consensus estimate of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. On average, analysts expect Astrazeneca to post $10 EPS for the current fiscal year and $11 EPS for the next fiscal year.

Astrazeneca Trading Up 0.2%

AZN opened at $168.68 on Friday. The firm’s fifty day moving average is $180.55 and its two-hundred day moving average is $188.02. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.71 and a current ratio of 0.91. The firm has a market cap of $261.61 billion, a PE ratio of 25.33, a price-to-earnings-growth ratio of 1.38 and a beta of 0.24. Astrazeneca has a twelve month low of $142.98 and a twelve month high of $212.71.

Analyst Ratings Changes

Several equities analysts have recently issued reports on AZN shares. Weiss Ratings lowered shares of Astrazeneca from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, June 18th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Tuesday, June 30th. Barclays reiterated a “buy” rating on shares of Astrazeneca in a report on Monday, June 1st. UBS Group reissued a “buy” rating on shares of Astrazeneca in a research note on Friday, April 10th. Finally, DZ Bank upgraded Astrazeneca from a “neutral” rating to a “buy” rating in a report on Wednesday, April 29th. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Astrazeneca has an average rating of “Moderate Buy” and an average price target of $211.00.

Institutional Investors Weigh In On Astrazeneca

Several large investors have recently made changes to their positions in the stock. Morgan Stanley lifted its position in Astrazeneca by 3.2% in the 4th quarter. Morgan Stanley now owns 13,878,726 shares of the company’s stock valued at $2,435,716,000 after acquiring an additional 432,939 shares in the last quarter. Citigroup Inc. increased its holdings in Astrazeneca by 65.3% during the 4th quarter. Citigroup Inc. now owns 6,154,760 shares of the company’s stock worth $1,080,160,000 after purchasing an additional 2,431,890 shares in the last quarter. Boston Partners increased its holdings in Astrazeneca by 5.2% during the 3rd quarter. Boston Partners now owns 5,247,449 shares of the company’s stock worth $405,047,000 after purchasing an additional 257,525 shares in the last quarter. Ameriprise Financial Inc. raised its stake in shares of Astrazeneca by 2.1% in the 2nd quarter. Ameriprise Financial Inc. now owns 5,046,992 shares of the company’s stock valued at $351,734,000 after purchasing an additional 104,625 shares during the period. Finally, Northern Trust Corp raised its stake in shares of Astrazeneca by 2.8% in the 4th quarter. Northern Trust Corp now owns 4,756,686 shares of the company’s stock valued at $834,798,000 after purchasing an additional 130,245 shares during the period. Institutional investors own 20.35% of the company’s stock.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.